- Home
- CRSR vs SNDX Comparison
CRSR vs SNDX Comparison
Compare CRSR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSR
- SNDX
- Stock Information
- Founded
- CRSR 1994
- SNDX 2005
- Country
- CRSR United States
- SNDX United States
- Employees
- CRSR N/A
- SNDX N/A
- Industry
- CRSR Computer Manufacturing
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CRSR Technology
- SNDX Health Care
- Exchange
- CRSR Nasdaq
- SNDX Nasdaq
- Market Cap
- CRSR 1.1B
- SNDX 974.9M
- IPO Year
- CRSR 2020
- SNDX 2016
- Fundamental
- Price
- CRSR $6.03
- SNDX $11.54
- Analyst Decision
- CRSR Buy
- SNDX Strong Buy
- Analyst Count
- CRSR 6
- SNDX 10
- Target Price
- CRSR $10.17
- SNDX $36.20
- AVG Volume (30 Days)
- CRSR 1.1M
- SNDX 1.9M
- Earning Date
- CRSR 05-06-2025
- SNDX 05-07-2025
- Dividend Yield
- CRSR N/A
- SNDX N/A
- EPS Growth
- CRSR N/A
- SNDX N/A
- EPS
- CRSR N/A
- SNDX N/A
- Revenue
- CRSR $1,316,379,000.00
- SNDX $23,680,000.00
- Revenue This Year
- CRSR $16.15
- SNDX $286.51
- Revenue Next Year
- CRSR $10.40
- SNDX $120.86
- P/E Ratio
- CRSR N/A
- SNDX N/A
- Revenue Growth
- CRSR N/A
- SNDX N/A
- 52 Week Low
- CRSR $5.60
- SNDX $9.66
- 52 Week High
- CRSR $13.02
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- CRSR 27.66
- SNDX 44.37
- Support Level
- CRSR $5.92
- SNDX $9.66
- Resistance Level
- CRSR $6.70
- SNDX $11.61
- Average True Range (ATR)
- CRSR 0.65
- SNDX 1.01
- MACD
- CRSR -0.12
- SNDX 0.02
- Stochastic Oscillator
- CRSR 7.23
- SNDX 56.12
About CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.